Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1

Journal of Immunotherapy

Volumn 28, Issue 3, 2005, Pages 252-257

  Le Gal, Frédérique Anne ^a   Ayyoub, Maha ^b   Dutoit, Valérie ^b   Widmer, Valérie ^a   Jäger, Elke ^c   Cerottini, Jean Charles ^d   Dietrich, Pierre Yves ^a   Valmori, Danila ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

^c KRANKENHAUS NORDWEST   (Germany)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Repertoire; T cell receptor; Tumor immunity; Vaccination

Indexed keywords

CANCER TESTIS ANTIGEN; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 17844403729     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000161398.34701.26     Document Type: Article

References (18)

1. Scanlan MJ, Gure AO, Jungbluth AA, et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002;188:22-32.
2. Gotter J, Brors B, Hergenhahn M, et al. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004;199:155-166.
3. Jäger E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med. 1998;187:265-270.
4. Valmori D, Dutoit V, Liénard D, et al. Naturally occurring HLA-A2 restricted CD8+ T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000;60:4499-4506.
5. Dutoit V, Taub RN, Papadopoulos KP, et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002;110:1813-1822.
6. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature. 1988;334:395-402.
7. Garcia KC, Degano M, Stanfield RL, et al. An alpha-beta T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science. 1996;274:209-219.
8. Valmori D, Dutoit V, Liénard D, et al. Tetramer-guided analysis of TCR b-chain usage reveals a large repertoire of Melan-A-specific CD8+ T cells in melanoma patients. J Immunol. 2000;165:533-538.
9. Lim A, Trautmann L, Peyrat MA, et al. Frequent contribution of T cell clonotypes with public TCR features to the chronic response against a dominant EBV-derived epitope: application to direct detection of their molecular imprint on the human peripheral T cell repertoire. J Immunol. 2000;165:2001-2011.
10. Argaet VP, Schmidt CW, Burrows SR, et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med. 1994;180:2335-2340.
11. Valmori D, Dutoit V, Ayyoub M, et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 2003;3:15.
12. Jäger E, Nagata Y, Gnjatic S, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA. 2000;97:4760-4765.
13. Dietrich PY, Le Gal FA, Dutoit V, et al. Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen. J Immunol. 2003;170:5103-5109.
14. Genevee C, Diu A, Nierat J, et al. An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol. 1992;22:1261-1269.
15. Arden B, Clark SP, Kabelitz D, et al. Human T-cell receptor variable gene segment families. Immunogenetics. 1995;42:455-500.
16. Chen W, Yewdell JW, Levine RL, et al. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med. 1999;189:1757-1764.
17. Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity. 1997;6:273-281.
18. Trautmann L, Labarriere N, Jotereau F, et al. Dominant TCRV alpha usage by virus and tumor-reactive T cells with wide affinity ranges for their specific antigens. Eur J Immunol. 2002;32:3181-3190.